-+ 0.00%
-+ 0.00%
-+ 0.00%

Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight

Barchart·08/18/2026 09:33:00
Listen to the news

The non-metastatic prostate cancer market is expected to witness significant growth, driven by increasing disease awareness, improved screening practices, and advances in early-stage diagnosis. Additionally, a growing pipeline of therapies such as Relugolix (ORGOVYX) (Myovant/Sumitomo Pharma/Takeda/Accord), CAN-2409 (Candel Therapeutics), KPG-121 (Kangpu Biopharmaceuticals), and others is expected to create new opportunities and strengthen market expansion in the coming years.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.